AstraZeneca shares fall about 1.3% after positive Phase 3 COPD results
AstraZeneca fell about 1.3% to $158 Wednesday, after its experimental COPD treatment reported positive Phase 3 results.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.